Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Xbrane Biopharma, Webcast, Q3'26

By Inderes10/30/2026, 8:00 AM
Xbrane Biopharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Martin CEO
00:01 - 17:38

Hello, my name is Martin, CEO of Xbrane. I have with me our CFO, Jane, and we will present the Q3 2026 report for the company. I will, as usual, go through a brief operational update related to the quarter, and Jane will thereafter go through the financial highlights. First, a snapshot of our development portfolio, starting with our biosimilar to Lucentis, which is under the brand name Ximluci on the market in Europe and select countries in the Middle East, and now recently got approved by the US FDA under the brand name Lucamzi. We have a partnership with STADA for the European market and a partnership with Valorum Biologics for future commercialization in the US. Our second product, Xdivane, is a biosimilar candidate to Opdivo, partnered with Intas and Accord Healthcare. We recently announced that the pivotal clinical pharmacokinetic trial was fully recruited. We are looking forward to the clinical readout in Q2 next year, followed by a submission of a BLA to the US FDA, and then Xdarzane, our Darzalex biosimilar candidate, which is in early stage development, partnered up with JOINN Biologics, which is conducting process development currently. In parallel to that, Xbrane is seeking commercialization partners for that product. But we'll go through this a little bit more in depth one by one and starting then with Lucamzi in the US. We are very happy, of course, with the recent FDA approval. We are now going through preparations with our partner for launch during the course of next year. And yes, a snapshot of the market. I think the right way to look at this is as anti-VEGF inhibitors for retinal disorders. That is a market of about €9 billion, with about 10 million units being administered annually across the US. So it is a very sizable market. There are about 16 products in that market as far as we can tell. Six branded or originator products, and ten biosimilars, both on Eylea and on Lucentis. So, I think for us, this poses a big opportunity. Of course, it is a very sizable market. And even if we were to capture just 1% of that market, it could reach sales of up to 100 million USD. So it's a very sizable market. And we are now, together with our partners, forming the commercial strategy for the product. So it is a little bit too early to say how this will pan out. But we can note that given the dynamics in the US market, new entrants are actually favored. In the segment of products which falls under Medicare Part B, due to the structure with reimbursement on the back, the list price before you have an average sales price established is essentially the list price minus the discounts that are given. So I think these dynamics typically favor new entrants because you are able to structure it so that it becomes economically beneficial for, in this case, the eye clinics. So we are quite optimistic that this will go well, and we will make the most out of this opportunity together with our partners. And I said what lies ahead of us. Before a launch is above all, of course, production of material. We are going through that during the remainder of this year, essentially, then preparations with our partner Valorum of course, which relates to applying for the so-called Q-code, which is required essentially for reimbursement upon administration of the product. I think this is crucial to have in place before launch. That takes six months to get in place. It is just an administrative process. So there is no risk or anything attached to that, but it is an application which needs to be processed. So therefore we should have that by mid next year, after which we believe a launch can take place. But as I said, this is really something we do now in collaboration with our partners. And now, a few words about Europe. And then a few words about Europe. As I said, Ximluci, which is the brand name in Europe, has been on the market since 2023 across 24 countries in Europe and the Middle East, with a quite simple commercialization structure. We have co-developed the product together with STADA, and we are sharing the profit contribution. 50/50, and here is a historical graph with the profit share essentially that has gone to Xbrane over the quarters since launch in Europe. And we have an accumulated profit sharing of about 145 million Swedish kronor throughout this time period. And you can see on this graph that it varies quite a bit from quarter to quarter. And it mostly has to do with the way this is accounted for, where actually the profit sharing is recognized as revenue upon shipment of the goods to STADA and the shipment goes in cycles. So that is why there is a little bit of variation quarter by quarter. But I think if we look at this, where we stand now, it's generating about 50 million Swedish kronor a year in profit sharing for Xbrane. With that said, we have a 6% volume market share, when looking at only the Ranibizumab market. So that's a share of the total VEGF inhibitor market. We are, as we have talked about before, going through several cost reduction measures. We believe that is crucial to bring down the production cost. Given an increase in competition. And this will bear fruit in the second half of next year, essentially. And we believe then that this could unlock further growth opportunities across Europe and the Middle East. We also have a remaining inventory position of 149 million Swedish crowns, essentially mainly drug substance gradually being converted to drug product. And so, to STADA mainly, we believe that will be converted during the remainder of this year and next year, essentially to cash. So that was an overview of where we stand with regards to Lucamzi or Ximluci, and shifting gear over to Xdivane, our biosimilar candidate to Opdivo. And so this is then targeting the whole PD-1 inhibitor market. So essentially Opdivo and Keytruda. And that is about €40 billion in annual net sales. So, a massive market opportunity. And it should be noted that Opdivo goes off patent first. So that's December 2028 in the US, and the Keytruda patent lapses some six months after. But we do believe there is an opportunity for biosimilars to be there day one, post-Opdivo patent expiration, to also capture market share from Keytruda. So massive market opportunity. And we believe we are well positioned from a timeline perspective in this race towards patent expiration. From a competitive perspective, we know Amgen already submitted their BLA to the FDA, but I do believe that we are second in that group of expected biosimilars. Having fully recruited our pivotal clinical trial. And then we have three other biosimilar candidates under development and in clinical trials. So eventually, we do expect to see five or so biosimilars to Opdivo on the market. But it is really about being there in the first wave, or preferably, upon patent expiration, which we really do believe that we are going to be able to be. A partnership with Accord Healthcare in relation to this product provides us with a very strong partner for commercialization. Accord Healthcare, which is a sales subsidiary of Intas, has a very high market share in Europe when it comes to oncology injectables. It is also establishing itself in the US with its acquisition of the Coherus Pegfilgrastim biosimilar a while ago. And also, a handful of products on their way to market. We believe we have a strong commercialization partner, and we are confident that Accord Healthcare will do a fabulous job in commercializing this product. And again, from a timeline perspective, we are now going through, on the one hand, all the CMC related activities which are remaining. So that is drug substance, drug product process validation and characterization, which is going according to plan. Again, the pivotal clinical trial was fully recruited with 340 patients in melanoma, and we are going to have an interim readout in Q2 next year. And then we are planning for a submission of a BLA to the FDA mid next year. We are preparing to receive approval and be in a position to launch by the patent expiration at the end of 2028. So I think this is going very much according to plan. Currently, I am very excited about the prospects of this program. Moving forward, I think a natural question to have, and a question we often get, is why should we believe that this biosimilar candidate is going to be approved on the first attempt by the FDA, given the delays we've had with Lucamzi. And it's a fair comment, but I think it's important to look at this in a little bit more detailed manner. What held us back with Lucamzi was really related to GMP issues at contract manufacturers, and it was related to unresolved observations from inspections by the FDA. We had two CRLs due to that. As you might recall, the FDA in the first BLA we sent in did not have any comments in relation to the clinical development nor the whole analytical comparability package, which are two other important aspects of the BLA. So we've learned from this when it comes to Xdivane, and we work with one of the top ten contract manufacturers globally with two sites involved, having had successful FDA inspections since 2010 and supplying commercial product to the US since. So we do believe that we have reduced the risk in relation to potential issues with the FDA related to inspections at manufacturing sites. And I do believe there is a high probability that we are going to get approved the first time when we submit the BLA to the FDA. So we're quite excited about this program and it could be very valuable to Xbrane. We have shown this slide before, and we had Venture Valuation, an independent pharmaceutical product valuation company located in Switzerland, perform an evaluation of Xdivane essentially. And you can see on the right-hand side of this slide all the assumptions that they took in this valuation, but it's essentially just looking at the expected market or the expected sales of the originator product by the time of launch. Looking at the trajectory of other oncology biosimilars in the US when it comes to volume, market share as well as price decline and applying those curves or trends to this situation in combination with the expected competitive situation, essentially. And then applying the relevant cost structure and profit sharing mechanism, and all that together. Their estimate was that this could generate about €100 million in profit sharing at its peak to Xbrane, which of course would be a fabulous and very sizable opportunity for us. So we're very excited about this program and what it could do for patients, of course, but also for Xbrane as a company. Then moving on to Xdarzane, this is more early-stage, as I mentioned, but we're quite excited about this program as well. It is addressing a very sizable originator product now at about 14 billion USD, actually. And we are navigating this through without having to invest further into the program from Xbrane's perspective. So essentially, the arrangement here is that JOINN Biologics, which is a prominent biologics CDMO with sites in both the US and China, is going through process development of this biosimilar candidate, and the target is to get towards comparative analytical demonstration by mid-next year, after which we can take this program further to scale up production of clinical material and go into the clinic, and so on, in parallel. Xbrane is seeking a commercialization partner, similar to the partnerships we have established with STADA as well as Intas in the past. We are seeking a similar structure with a partner that is interested in commercializing this biosimilar candidate once approved. So early stage, but quite interesting opportunity still. So, to summarize, the key takeaways from this quarter. Ximluci launched across 24 countries in Europe and the MENA region, generating about 50 million Swedish kronor per year in profit sharing for us now. We are going through cost reduction measures, which will bear fruit in the second half of next year and, we hope, unlock further growth opportunities. Lucamzi has received FDA approval and we are now going through preparations for launch during the course of next year, together with our partners. And then for Xdivane, the pivotal pharmacokinetic trial was fully recruited in October, and we are moving in a timely fashion toward a day one launch in the US, late 2028. And then early development will start, Xdarzane, and we are working through establishing a deal with a commercialization partner. So these are the key takeaways from an operational perspective of the quarter. And I therefore hand over to Jane to go through the financial highlights.

Jane CFO
17:39 - 20:06

Yes. And as we can see during the third quarter, we have resumed shipments to STADA, giving us a total revenue of 54.8 million Swedish crowns. Whereof 54.6 million Swedish crowns are referred to. Shipments to STADA COGS amounted to 45.8 million Swedish crowns, giving us a gross margin of 16%. We expect continued shipments to STADA during the course of the coming quarters, and as Martin mentioned, we are still working on cost-reducing measures to reduce our cost of goods and achieve a more competitive cost of goods and production costs in 2027 and onwards. Administrative expenses amounted to 5.4 million Swedish kronor and the R&D expenses to 13.4 million Swedish kronor. Whereof 2.7 million Swedish crowns referred to amortization of intangible assets and 15.7 million Swedish crowns have been capitalized as intangible assets during the third quarter of 2026. Here you can see the cash flow breakdown for the third quarter. So 6 million Swedish crowns was received from profit sharing from STADA for the second quarter, and production of finished goods of Ximluci amounted to 3 million Swedish crowns, which will give us and has given us revenue during the third quarter and also in the upcoming quarters. Fixed costs amounted to 17 million Swedish kronor and refer to salaries, social security, IT, storage, etc. Ximluci sales gave us 39 million Swedish crowns, which came from accounts receivables for the second quarter and also current sales. During the third quarter, development costs amounted to 5 million Swedish crowns in cash flow and Xdivane to 3 million Swedish crowns, referring to CMC-related development costs. So the cash balance closed at 37.4 million Swedish crowns, which all in all gave us an operating cash flow for the quarter amounting to 4.1 million Swedish crowns.

Martin CEO
20:12 - 20:22

Excellent. So we thereby close the formal presentation and open up for potential questions from listeners calling in.

Operator
20:23 - 20:27

The next question comes from Fredrik Thor from Redeye. Please go ahead.

Fredrik Thor
20:29 - 20:43

Hello and thank you. And congratulations on the approval. So my first question was about volume growth for Ximluci, which you showed us. But if you can just elaborate a bit and also on the market share dynamics.

Martin CEO
20:46 - 21:01

The volume market share for Ximluci across Europe was 6% as of July. The volume growth in the quarter. Martin?

Jane CFO
21:03 - 21:31

Well, we haven't seen any real volume growth. The total market has been declining a little bit due to increased competition coming from other treatments. Unfortunately, as a total, the Ranibizumab market has been declining and the growth for Ximluci has more or less stayed the same.

Fredrik Thor
21:34 - 21:49

Got it. And in the presentation, you also mentioned that the time to launch in the US is quite a bit into 2027. What is the timeline in place before the launch?

Martin CEO
21:52 - 22:35

Yes, first of all, of course, to produce material and ship to our partner in the US, but I think the most time-limiting element here is related to this Q-code, which needs to be applied for and received. And that takes six months. That is the time the application process takes. And you can submit that by the end of each quarter. So effectively, our partner is going to submit that by the end of this quarter and have it in place by the end of Q2 next year. So that is probably the most time-limiting factor for an upcoming launch.

Fredrik Thor
22:38 - 23:03

Got it. You will also mention the learnings from the FDA process. I believe it was mostly about contract manufacturing, but have you learned how much we gained in other areas regarding applications to the US, for example, the use of consultants and how to prepare an application and so on. It would be interesting to hear a bit more.

Martin CEO
23:04 - 24:09

I think we are gradually learning a lot, actually. One key aspect, of course, when it comes to Xdivane, if I compare it to Ximluci, is the clinical trial in itself, where we were one of the first companies to get acceptance from both EMA and FDA to conduct a pharmacokinetic comparative study instead of looking at an efficacy endpoint for comparative purposes. So we managed to reduce the size of that trial significantly and therefore also the time to conduct the clinical trial and the cost. So I think this was a crucial development. You know, this development from Ximluci to Xdivane demonstrates how we run these programs. I do think that there is much. There is much that we are still learning, which can be applied and will be applied to future programs. It all centers around bringing down the timeline and bringing down the cost for development.

Fredrik Thor
24:12 - 24:40

Got it. And a final question. You mentioned the refinancing of the outstanding debt. Yeah. And the ongoing discussions. But what about the payments from Valorum? Is that included in these calculations or is it on top of that? Or how do you balance between renegotiation and financing and using the potential milestone from the approval in the US?

Martin CEO
24:41 - 26:14

Yeah. As we have said before, the financial terms in the agreement with Valorum are subject to an ongoing amendment discussion or negotiation, essentially, which now is going to be completed between the parties. So we cannot really comment further on any financial deal details in relation to the agreement with Valorum that needs to be finalized, if you will, during the coming weeks or months. And then when it comes to the outstanding debt, we talked about this before in relation to the Q2 report, and I think we stated the same now, that essentially we have a cash position with which we can manage. Up until the end of next year or so, if we do not include potential incomes from the US nor repayment of debt. So hence, given that we are currently having discussions with them, of course, and with other potential investors with regards to potential refinancing of that debt. Also, this is something we will have to get back to you on during the coming months.

Fredrik Thor
26:16 - 26:19

Got it. That is all for me. Thank you very much.

Martin CEO
26:20 - 27:45

Thank you. If there are no further questions from people on the line, let's proceed. We have three questions here in the chat. The first one: any updates regarding the agreement with Valorum Biologics? I think we discussed that. The second question is: when can we expect a resolution regarding the financial situation with Fanya? I have also discussed that one. Yeah. And the second and the third question in relation to the loan with JOINN Biologics. I believe these three questions have already been addressed by the inquiries submitted. And one new question that came in. Now, any updates on the pre-filled syringe? I think this refers to Ximluci/Lucamzi. This is something we discussed a few quarters ago, noting that it has been paused, given essentially how the market has developed and our resource situation in finalizing the development of the prefilled syringe. If we are going to take this up again, we will get back to the market with regards to communication in relation to that.

Operator
27:52 - 27:58

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Martin CEO
28:02 - 28:32

Yeah. We will upload this presentation along with the recording on our web page. And with that said, I thank you all for calling in. And if you have any further questions, we are here. Myself and Jane, you can reach us over phone or email and we will do our best to respond to your questions. I wish you a good rest of the day.

Jane CFO
28:33 - 28:33

Thank you.

Martin CEO
28:33 - 28:34

Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…